Left ventricular hypertrophy is one of the most common clinical cardiac entity.It is recognised either by ECG or echocardiography.LVH has a unique place in cardiology as it can imply a grossly pathological state or a marker of healthy heart as in physiological hypertrophy in athletes.
Logic would suggest , in this era of stem cells and [...]
Archive for September 10th, 2008
Advantages of Left ventricular hypertrophy (LVH)
Posted in Cardiology - Clinical, Infrequently asked questions in cardiology (iFAQs), cardiology- coronary care, tagged acs, atheletes heart, cardiac failure, cardiac reserve, cardiology, coronary, framingham study, hypertension, left ventricular hypertrophy, LV mass, lvh, myocardium, nstemi, pci, ptca, stemi on September 10, 2008 | 1 Comment »
Why thrombolysis is contraindicated in unstable angina ?
Posted in Cardiology - Clinical, Infrequently asked questions in cardiology (iFAQs), cardiology- coronary care, tagged acs, angioplasty, aspirin, bmj, cardiology, clopidogrel, clot, coronary thrombosis, drsvenkatesan, eptifibatide, fibrinolytics, fuster, heparin, jacc, lancet, madras medical college, nejm, nstemi, pci, platelet, ptca, red clot, reteplace, stemi, streptokinase, thrombolytic agents, tisue plasminogen activator, tnk tpa, tpa, unstable angina, virchow, white clot on September 10, 2008 | Leave a Comment »
Intra coronary thrombosis is the sine qua non of acute coronary syndrome ( Both STEMI and NSTEMI.) But thrombolysis is the specific therapy in STEMI and is contraindicated in NSTEMI/UA.
Why is this apparent paradox ? What is basic differnce between UA and AMI ?
In STEMI there is a sudden & total occlusion of a coronary artery [...]
Archives
Pages
Meta
-
